COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
The present invention is directed to methods and compositions for systemic delivery of minimally- soluble bioactive agents such as, but not limited to, proteins of the TGF-ß superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-in...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention is directed to methods and compositions for systemic delivery of minimally- soluble bioactive agents such as, but not limited to, proteins of the TGF-ß superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
La présente invention concerne des procédés et des compositions permettant une administration systémique d'agents bioactifs très peu solubles tels que, mais la liste n'est pas limitative, les protéines de la superfamille des TGF-ß. Selon l'invention, un exemple d'agent bioactif est le BMP-7. L'invention concerne, en outre, un traitement systémique le moins invasif possible des troubles squelettiques tels que l'ostéoporose, de même qu'un traitement systémique le moins invasif possible de tissus et d'organes non minéralisés lésés ou malades, tels que les reins. La mise en oeuvre de l'invention permet d'éviter tout effet indésirable au niveau du site de l'administration intravasculaire dudit agent bioactif. |
---|